The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

  • Lowest Price Guaranteed From USD 3,499

  • Published
    August 2018

  • Pages
    455

  • View Count
    9458

Example Insights

   

 

Overview

The rate of outsourcing is definitely increasing at a fast pace. In my opinion, approximately 60% of antibody discovery services are presently being outsourced to contract service providers. In the future, we can expect close to 90% of such operations to be outsourced

-CEO & Co-Founder, a US based small-sized platform provider

Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages. It is worth mentioning that the research and development efforts associated with antibody-based therapeutics have significantly paced up in 2017; this momentum is projected to continue over the coming several years. In fact, in 2017, more than 10 monoclonal antibodies were approved by the FDA and EMA. Additionally, close to 20 monoclonal antibodies are currently being evaluated in late stages of clinical development.In addition to monoclonal antibodies, other novel antibody-based therapeutics, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, are steadily gaining traction.

The discovery of antibodies is a long, arduous and cost intensive process. As a result, many biopharmaceutical developers are opting to outsource such operations. Modern contract research organizations (CROs), offering antibody discovery services, claim to have novel and advanced technologies to support players developing antibody-based products in their early stage research requirements. Additionally, there are a number of companies that have developed proprietary antibody discovery platforms and have made them available to drug developers. In-licensing the technology of such players for use in drug discovery operations is considered a viable business strategy, offering both time and cost related benefits to drug / therapy developers. As the demand for such therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to grow in the foreseen future.

 

Scope of the Report

The Antibody Discovery: Services and Platforms (2nd Edition), 2018-2028 report provides an extensive studyon the current market landscape and future outlook of companies offering antibody discovery services and platforms. Amongst various elements, the report includes:

  • A detailed assessment of the current market landscape of companies offering antibody drug discovery services, including information on their geographical location, types of services offered (antigen designing, hit generation, lead selection, and lead optimization / and lead characterization), antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), purpose of antibody discovery (therapeutic and diagnostic) and animal models used (rabbits, rats, mouse, llamas, chicken and others).
  • An in-depth analysis of antibody platform providers, featuring information on their geographical location, antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), type of antibodies discovered (ADCs, antibody fragments, bispecific antibodies, monoclonal antibodies and others), and animal models used (transgenic mice, rabbits, llamas and others).
  • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large sized companies, comparing their existing capabilities within and beyond their respective peer groups, and providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
  • A comparative landscape of service providers, highlighting the most important companies within North America, Europe and Asia Pacific, based on number of discovery services offered, number of discovery methods available, number of subject specific agreements signed, the company’s experience and size of employee base.
  • An insightful 2X2 competitiveness analysis of various antibody discovery platforms (segregated into three peer groups, namely library based method, transgenic mice, single cell based method), highlighting popular products based on the library size of the platform, types of antibody discovered, need for humanization, platform-specific collaborations established per year, therapeutic areas addressed and supplier power (in terms of experience of the company).
  • Comprehensive profiles of antibody discovery service and platform providers, featuring information on the location of their headquarters, year of establishment, antibody discovery service / platform portfolio, recent developments and a comprehensive future outlook.
  • A case study on antibody humanization and affinity maturation, including an exemplary list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends related to this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • An analysis of the partnerships that have been established in the recent past, covering research collaborations, licensing agreements (related to both technology platforms and service providers), product development, service agreements, merger / acquisitions and othersforms of collaborations.
  • An analysis of investments received by the service and platform providers, featuring details of capital raised via seed financing, venture capital financing, IPOs, debt financing and grants / awards, by companies that are operating within this domain.
  • A discussion on the upcoming opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. We have provided insights on the likely evolution of the market in different regions, including North America, Europe, China and the rest of the world. In addition, we have provided the likely distribution of the opportunity across the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), and the nature of antibody generated (chimeric, humanized and fully human). In addition, we have estimated the future opportunity for platform providers in term of the likely licensing deal structures and the agreements that are expected to be signed in the foreseen future.The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Aaron Sato (Chief Scientific Officer, LakePharma)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Garren Hilow (Co-Founder and Chief Executive Officer, Abveris)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Ignacio Pino (President and Chief Executive Officer, CDI Laboratories)
  • Jeng Her (Chief Executive Officer, AP Biosciences)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term.

Chapter 3  provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, namely, monoclonal, bispecific and polyclonal antibodies.

Chapter 4  features information on the antibody discovery process and the various methods used in the discovery of such therapeutic biomolecules. It also includes a comparison of the different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5  includes a comprehensive market landscape analysis of companies that offer antibody discovery services and / or have proprietary discovery platforms. For antibody discovery service providers, the chapter presents detailed analyses on the basis of their geographical location, types of services offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), purpose of antibody discovery (therapeutic and diagnostic) and animal models used (rabbits, rats, mouse, llamas, chicken and others). For antibody discovery platform providers, the chapter includes analyses based on geographical location, antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), types of antibodies discovered (ADCs, antibody fragments, bispecific antibodies, monoclonal antibodies and others), and animal models used (transgenic mice, rabbits, llamas and others). Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs.

Chapter 6  presents a benchmark analysis of all the service providers engaged in this domain. It highlights the capabilities of the various companies in terms of their expertise across antibody discovery, enabling players to compare their existing capabilities within and beyond their respective peer groups and to identify opportunities to become more competitive in the industry.

Chapter 7  provides a comparative landscape of the service providers based on various parameters, such as the number of antibody discovery services offered, number of methods used for the discovery of antibodies, number of collaborations established in the recent past specifically focusing on the discovery and generation of antibodies, company size and experience. Based on the aforementioned analysis, the chapter highlights the most active players within North America, Europe and Asia-Pacific, in a 2X2 matrix.

Chapter 8  providesdetailed profiles of some of the important players, based in different geographies,which are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, financial information ( if available ), details on antibody discovery services and novel antibody discovery technology / platforms, and a comprehensive future outlook.

Chapter 9  featuresa comprehensive 2X2 analysis offering a comparative summary of all the technology platforms that we came across during our research. The analysis compares the aforementioned platforms within four groups [A] library-based technologies [B] transgenic mice-based technology platforms, [C] single cell-based technologies and [D] others. The platforms were compared based on the library size of the platform, types of antibodies discovered, need for humanization, platform-specific collaborations established per year, therapeutic areas addressed and supplier power (in terms of experience of the company).

Chapter 10  providesdetailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, financial information ( if available ), details on antibody discovery technology / platformsand a comprehensive future outlook.

Chapter 11  features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including research collaborations, licensing agreements (related to both technology platforms and service providers), product development, service agreements and merger / acquisitions) and the most common forms of deals / agreements that have been established in the period between 2011 to 2018.

Chapter 12  presents details on various investments received by the companies that are engaged in this domain. It also includes a detailed analysis of the funding instances that have taken place in the period January 2009 to May 2018, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 13  presentsa comprehensive market forecast analysis, highlighting the future potential of the antibody discovery services domain till the year 2028. It features the likely distribution of the upcoming opportunity across [A] key geographies, namely North America, Europe (Germany, Switzerland, UK, France, Belgium and the rest of the Europe), Asia Pacific and rest of the world, [B] steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [C] antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and [D] the nature of antibody generated (murine, chimeric, humanized and fully human). In addition, we have provided a view on the likely upfront and milestone payments to be made in the licensing deals signed or planned with the focus on antibody discovery.

Chapter 14  provides detailed profiles on the top five therapeutic antibody products, which have generated the highest sales till 2017. Each profile covers information on the drug overview, historical sales, and discovery process and methods. The chapter provides information on Humira®, Rituxan®, Herceptin®, Remicade®and Avastin®.

Chapter 15  features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents an exemplary list of key players along with information on location of these companies, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models used by the players involved in this domain. In addition, chapter presents a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 16  provides an overview of future growth opportunities associated with the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have a notable influence on the industry’s evolution over the coming decade.

Chapter 17  presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in development of therapeutics for Parkinson’s disease. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 18  is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with ( in alphabetical order of person name ) Aaron Sato (Chief Scientific Officer, LakePharma), Christel Iffland (Vice President, Ligand Pharmaceuticals), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Debra Valsamis (Business Development Associate, Antibody Solutions), Garren Hilow (Co-Founder and Chief Executive Officer, Abveris), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita), Sanjiban K Banerjee (Director, AbGenics Life Sciences), , and Thomas Schirrmann (CEO and General Manager, YUMAB).

Chapter 19  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20  is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contacts

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Discovery
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies
3.7. Applications of Antibodies
 
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
 
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In Vitro Display Methods
4.3.2.1. Phage Display Method
4.3.2.2. Yeast Display Method
4.3.2.3. Ribosomal Display Method
4.3.3. Transgenic Animals Based Method
4.3.4. Single B Cell Based Method
 
4.4. Advantages and Disadvantages of Antibody Discovery Methods
4.5. Evolution of Monoclonal Antibodies
4.5.1. Fully Human Monoclonal Antibodies
 
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: Overall Market Landscape
5.2.1. Analysis by Antibody Discovery Steps
5.2.2. Analysis by Antibody Discovery Methods
5.2.3. Analysis by Purpose of Antibody Discovery
5.2.4. Analysis by Type of Antibodies Discovered
5.2.5. Analysis by Animal Model Used
 
5.3. Antibody Discovery Platform Providers: Overall Market Landscape
5.3.1. Analysis by Antibody Discovery Methods
5.3.2. Analysis by Type of Antibodies Discovered
5.3.3. Analysis by Animal Model Used
5.3.4. Antibody Discovery Service and Platform Providers: Analysis by Geographical Location
 
5.4. Antibody Discovery Platform Providers: for In-house Purposes
 
6. BENCHMARK ANALYSIS
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups
6.4. Benchmark Analysis: North America Based Companies
6.4.1. Peer Group I
6.4.2. Peer Group II
6.4.3. Peer Group III
6.5. Benchmark Analysis: Europe and Asia Pacific Based Companies
6.5.1. Peer Group IV
6.5.2. Peer Group V
6.5.3. Peer Group VI
 
7. COMPARATIVE ANALYSIS OF SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: Competitive Landscape
7.3. Antibody Discovery Service Providers: Comparative Analysis by Region
7.3.1. Key Players in North America
7.3.2. Key Players in Europe
7.3.3. Key Players in Asia Pacific
 
8. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
8.1. Chapter Overview
8.2. Antibody Discovery Service Providers in North America
8.2.1. Abwiz Bio
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Antibody Discovery Services
8.2.1.4. Antibody Discovery Platforms
8.2.1.4.1. Needle-in-a-Haystack Technology™
8.2.1.4.2. RabWiz™
8.2.1.4.3. WizAmp™
8.2.1.5. Recent Developments
8.2.1.5.1. Partnerships
8.2.1.6. Future Outlook
 
8.2.2. Aragen Bioscience (A GVK BIO Company)
8.2.2.1. Company Overview
8.2.2.2. Antibody Discovery Services
8.2.2.3. Recent Developments
8.2.2.3.1. Expansions
8.2.2.3.2. Partnerships
8.2.2.4. Future Outlook
 
8.2.3. Integral Molecular
8.2.3.1. Company Overview
8.2.3.2. Financial Information
8.2.3.3. Antibody Discovery Services
8.2.3.4. Recent Developments
8.2.3.5. Future Outlook
 
8.2.4. LakePharma
8.2.4.1. Company Overview
8.2.4.2. Antibody Discovery Services
8.2.4.3. Recent Developments
8.2.4.3.1. Expansions
8.2.4.3.2. Partnerships
8.2.4.4. Future Outlook
 
8.3. Antibody Discovery Service Providers in Europe
8.3.1. Abzena
8.3.1.1. Company Overview
8.3.1.2. Financial Information
8.3.1.3. Antibody Discovery Services
8.3.1.4. Recent Developments
8.3.1.4.1. Expansions
8.3.1.4.2. Partnerships
8.3.1.5. Future Outlook
 
8.3.2. MAB Discovery
8.3.2.1. Company Overview
8.3.2.2. Financial Information
8.3.2.3. Antibody Discovery Services
8.3.2.4. Recent Developments
8.3.2.5. Future Outlook
 
8.3.3. ModiQuest Research (Acquired by ImmunoPrecise Antibodies)
8.3.3.1. Company Overview
8.3.3.2. Antibody Discovery Services
8.3.3.3. Antibody Discovery Platforms
8.3.3.3.1. ModiVacc™
8.3.3.3.2. ModiFuse™: Proprietary Hybridoma Platform
8.3.3.3.3. ModiSelect™: Proprietary B Cell Selection Platform
8.3.3.3.4. ModiPhage™: In-House and Custom Phage Libraries
8.3.3.3.5. ModiTune™: Antibody Optimization Platform
8.3.3.3.6. ModiXpress™: Proprietary In-House Expression Platform
8.3.3.4. Recent Developments
8.3.3.4.1. Partnerships
8.3.3.5. Future Outlook
 
8.3.4. PX'Therapeutics (Acquired by Aguettant Pharmaceutical Group)
8.3.4.1. Company Overview
8.3.4.2. Antibody Discovery Services
8.3.4.3. Recent Developments
8.3.4.3.1. Partnerships
8.3.4.4. Future Outlook
 
8.4. Antibody Discovery Service Providers in Asia-Pacific
8.4.1. ChemPartner
8.4.1.1. Company Overview
8.4.1.2. Antibody Discovery Services
8.4.1.3. Recent Developments
8.4.1.3.1. Expansions
8.4.1.3.2. Partnerships
8.4.1.4. Future Outlook
 
8.4.2. Viva Biotech
8.4.2.1. Company Overview
8.4.2.2. Antibody Discovery Services
8.4.2.3. Recent Developments
8.4.2.3.1. Partnerships
8.4.2.4. Future Outlook
 
8.4.3. WuXi AppTec
8.4.3.1. Company Overview
8.4.3.2. Financial Information
8.4.3.3. Antibody Discovery Services
8.4.3.4. Recent Developments
8.4.3.4.1. Expansions
8.4.3.4.2. Partnerships
8.4.3.5. Future Outlook
 
9. COMPETITIVENESS ANALYSIS OF ANTIBODY DISCOVERY PLATFORMS
9.1. Chapter Overview
9.2. Library Based Antibody Discovery Platforms
9.3. Transgenic Animal Based Antibody Discovery Platforms
9.4. Single Cell Based Antibody Discovery Platforms
9.5. Other Antibody Discovery Platforms
 
10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. Antibody Discovery Platform Providers in North America
10.2.1. Distributed Bio
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. Antibody Discovery Platforms
10.2.1.3.1. SuperHuman Platform
10.2.1.4. Recent Developments
10.2.1.5. Future Outlook
 
10.2.2. Invenra
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. Antibody Discovery Platforms
10.2.2.3.1. B-Body™ Platform
10.2.2.4. Recent Developments
10.2.2.5. Future Outlook
 
10.2.3. Ligand Pharmaceuticals
10.2.3.1. Company Overview
10.2.3.2. Financial Information
10.2.3.3. Antibody Discovery Platforms
10.2.3.3.1. OmniAb
10.2.3.4. Patent Portfolio
10.2.3.5. Recent Developments
10.2.3.6. Future Outlook
 
10.2.4. Sorrento Pharmaceuticals
10.2.4.1. Company Overview
10.2.4.2. Financial Information
10.2.4.3. Antibody Discovery Platforms
10.2.4.3.1. G-MAB™ Technology
10.2.4.4. Recent Developments
10.2.4.5. Future Outlook
 
10.2.5. TRIANNI
10.2.5.1. Company Overview
10.2.5.2. The Trianni Mouse™ Platform
10.2.5.3. Patent Portfolio
10.2.5.4. Recent Developments
10.2.5.5. Future Outlook
 
10.2.6 Single Cell Technology
10.2.6.1. Company Overview
10.2.6.2. Financial Information
10.2.6.3. Antibody Discovery Platforms
10.2.6.3.1. AbTHENEUM™
10.2.6.4. Recent Developments
10.2.6.5. Future Outlook
 
10.3. Antibody Discovery Platform Providers in Europe
10.3.1. AIMM Therapeutics
10.3.1.1. Company Overview
10.3.1.2. Financial Information
10.3.1.3. Antibody Discovery Platforms
10.3.1.3.1. AIMSelect Platform
10.3.1.4. Recent Developments
10.3.1.5. Future Outlook
 
10.3.2. BioInvent
10.3.2.1. Company Overview
10.3.2.2. Financial Information
10.3.2.3. Antibody Discovery Platforms
10.3.2.3.1. n-CoDeR Antibody Library
10.3.2.4. Recent Developments
10.3.2.5. Future Outlook
 
10.3.3. Genmab
10.3.3.1. Company Overview
10.3.3.2. Financial Information
10.3.3.3. Antibody Discovery Platforms
10.3.3.3.1. DuoBody Technology
10.3.3.4. Recent Developments
10.3.3.5. Future Outlook
 
10.3.4. Kymab
10.3.4.1. Company Overview
10.3.4.2. Financial Information
10.3.4.3. Antibody Discovery Platforms
10.3.4.3.1. Kymouse™ Platform
10.3.4.4. Patent Portfolio
10.3.4.5. Recent Developments
10.3.4.6. Future Outlook
 
10.4. Antibody Discovery Platform Providers in Asia-Pacific
10.4.1. Harbour BioMed
10.4.1.1. Company Overview
10.4.1.2. Financial Information
10.4.1.3. Antibody Discovery Platforms
10.4.1.3.1. H2L2
10.4.1.3.2. HCAb
10.4.1.4. Patent Portfolio
10.4.1.5. Recent Developments
10.4.1.6. Future Outlook
 
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Antibody Discovery Service and Platform Providers: List of Partnerships and Collaborations
11.3.1. Analysis by Number of Partnerships
11.3.2. Analysis by Type of Partnership
11.3.3. Most Active Players: Analysis by Number of Partnerships
11.4. Concluding Remarks
 
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. Antibody Discovery Services and Platforms Market: Funding and Investment Analysis
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Most Active Players
12.3.5. Analysis by Most Active Investors
12.4. Concluding Remarks
 
13. OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology
13.3. Antibody Discovery Services Market, 2018-2030 (USD Billion)
13.4. Antibody Discovery Services Market, 2018-2030: Distribution by Geography (USD Billion)
13.4.1. Antibody Discovery Services Market: North America, 2018-2030 (USD Billion)
13.4.2. Antibody Discovery Services Market: Europe, 2018-2030 (USD Billion)
13.4.3. Antibody Discovery Services Market: China, 2018-2030 (USD Billion)
13.4.4. Antibody Discovery Services Market: Rest of the World, 2018-2030 (USD Billion)
13.4.5. Market Attractiveness Analysis by Region
13.5. Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps (USD Billion)
13.6. Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods (USD Billion)
13.6.1. Market Attractiveness Analysis by Antibody Discovery Method
13.7. Antibody Discovery Services Market, 2018-2030: Distribution by Type of Antibody Generated (USD Billion)
13.8. Antibody Discovery Platforms Market, 2018-2030: Licensing Deals (USD Billion)
13.9. Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030
 
14. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
14.1. Chapter Overview
14.2. Humira (Adalimumab)
14.2.1. Drug Overview
14.2.2. Discovery Process and Method
14.2.3. Historical Sales
 
14.3. Rituxan (Rituximab)
14.3.1. Drug Overview
14.3.2. Discovery Process and Method
14.3.3. Historical Sales
 
14.4. Herceptin (Trastuzumab)
14.4.1. Drug Overview
14.4.2. Discovery Process and Method
14.4.3. Historical Sales
 
14.5. Remicade (Infliximab)
14.5.1. Drug Overview
14.5.2. Discovery Process and Method
14.5.3. Historical Sales
 
14.6. Avastin (Bevacizumab)
14.6.1. Drug Overview
14.6.2. Discovery Process and Method
14.6.3. Historical Sales
 
15. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
15.1. Importance of Antibody Humanization and Affinity Maturation
15.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
15.3. Antibody Humanization: Publication Analysis
15.3.1. Publication Analysis: Year-Wise Trend
15.3.2. Publication Analysis: Key Journals
15.3.3. Publication Analysis: Distribution by Animal Model Used
15.3.4. Publication Analysis: Distribution by Method Used for Humanization
15.4. Antibody Humanization Service and Platform Providers: SWOT Analysis
 
16. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
16.1. Chapter Overview
16.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
16.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
16.4. Transition to CADD-based Approaches
16.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
16.6. Growing Market Opportunities in the Asia-Pacific Region
16.7. Expected Increase in Number of Collaborations and Licensing Activity
 
17. SURVEY INSIGHTS
17.1. Chapter Overview
17.2. Designation of Respondents
17.3. Antibody Discovery Stages
17.4. Antibody Discovery Methods
17.5. Type of Antibody Discovered
17.6. Location of Antibody Discovery Facility / Laboratory
17.7. Likely Market Size
 
18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Aaron Sato, Chief Scientific Officer, LakePharma
18.3. Christel Iffland, Vice President, Ligand Pharmaceuticals
18.4. Chun-Nan Chen, Chief Executive Officer & Chief Scientific Officer, Single Cell Technology
18.5. Debra Valsamis, Business Development Associate, Antibody Solutions
18.6. Garren Hilow, Co-Founder and Chief Executive Officer, Abveris
18.7. Giles Day, Co-Founder and Chief Executive Officer, Distributed Bio
18.8. Ignacio Pino, President and Chief Executive Officer, CDI Laboratories
18.9. Jeng Her, Chief Executive Officer, AP Biosciences
18.10. Kevin Heyries, Co-Founder and Lead of Business Development Strategy, AbCellera
18.11. Nalini Ghag- Motwani, President and Founding Chief Scientist, BioSavita
18.12. Sanjiban K Banerjee, Director, AbGenics Life Sciences
18.13. Thomas Schirrmann, Chief Executive Officer and General Manager, YUMAB
 
19. APPENDIX 1: TABULATED DATA
 
20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Applications of Antibodies
Figure 4.1 Overview of the Antibody Discovery Process
Figure 4.2 Antibody Discovery Process: Hybridoma Method
Figure 4.3 Antibody Discovery Process: Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibody Therapeutics
Figure 4.7 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Figure 5.1 Antibody Discovery Service Providers: Distribution by Antibody Discovery Steps
Figure 5.2 Antibody Discovery Services Providers: Antibody Discovery Methods
Figure 5.3 Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
Figure 5.4 Antibody Discovery Service Providers: Distribution by Type of Antibodies Discovered 
Figure 5.5 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 5.6 Antibody Discovery Platform Providers: Distribution by Antibody Discovery Methods
Figure 5.7 Antibody Discovery Platform Providers: Distribution by Type of Antibodies Discovered 
Figure 5.8 Antibody Discovery Platform Providers: Distribution by Animal Model Used
Figure 5.9 Antibody Discovery Service and Platform Providers: Geographical Distribution
Figure 6.1 Benchmark Analysis: Regional Distribution of Companies by Year of Establishment
Figure 6.2 Benchmark Analysis: North America Based Companies, Peer Group I
Figure 6.3 Benchmark Analysis: North America Based Companies, Peer Group II
Figure 6.4 Benchmark Analysis: North America Based Companies, Peer Group III
Figure 6.5 Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group IV
Figure 6.6 Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group V
Figure 6.7 Benchmark Analysis: Europe and Asia-Pacific   Based Companies, Peer Group VI
Figure 7.1 Antibody Discovery Service Providers: Competitive Landscape in North America
Figure 7.2 Antibody Discovery Service Providers: Competitive Landscape in Europe
Figure 7.3 Antibody Discovery Service Providers: Competitive Landscape in Asia-Pacific
Figure 8.1 Abwiz Bio: Antibody Discovery Services
Figure 8.2 LakePharma: Antibody Discovery Services
Figure 8.3 Abzena: Antibody Discovery Services
Figure 8.4 ChemPartner: Antibody Discovery Services
Figure 9.1 Platform Competitiveness Analysis:  Library Based Antibody Discovery Platforms
Figure 9.2 Platform Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
Figure 9.3 Platform Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
Figure 9.4 Platform Competitiveness Analysis: Other Platforms
Figure 10.1 Ligand Pharmaceuticals: Technology Portfolio
Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2012- Q1 2018 (USD Million)
Figure 10.3 AIMM Therapeutics: Technology Platforms
Figure 10.4 Sorrento Therapeutics: Technology Platforms
Figure 10.5 Genmab: Technology Platforms
Figure 11.1 Distribution by Number of Collaborations
Figure 11.2 Distribution by Type of Partnership 
Figure 11.3 Year-Wise Distribution by Type of Collaboration
Figure 11.4 Distribution by Type of Partnership Among Platform and Service Providers
Figure 11.5 Leading Players by Number of Partnerships
Figure 11.6 Key Focus Areas
Figure 11.7 Antibody Discovery Services and Platforms Collaborations: Novel Antibody Types (2017-2018)
Figure 12.1 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year, 2009-2018
Figure 12.2 Funding and Investment Analysis: Distribution of Average Funding Amount by Year, 2009-2018 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Amount Invested by Year, 2009-2018 (USD Million)
Figure 12.4 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Figure 12.5 Funding and Investment Analysis: Number of Funding Instances by Type of Funding, 2009-2013 and 2014-2018
Figure 12.6 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Figure 12.7 Funding and Investment Analysis: Distribution by Amount of Funding, 2009-2018
Figure 12.8 Funding and Investment Analysis: Most Active Players 
Figure 12.9 Funding and Investment Analysis: Most Active Investors 
Figure 12.10 Funding and Investment Summary
Figure 13.1 Antibody Discovery Services Market, 2018-2030: Base Scenario (USD Billion)
Figure 13.2 Antibody Discovery Services Market, 2018 and 2028: Distribution by Geography, Base Scenario (USD Billion)
Figure 13.3 Antibody Discovery Services Market, 2018-2030: North America, Base Scenario (USD Billion)
Figure 13.4 Antibody Discovery Services Market, 2018-2030: Europe, Base Scenario (USD Billion)
Figure 13.5 Antibody Discovery Services Market, 2018-2030: China, Base Scenario (USD Billion) 
Figure 13.6 Antibody Discovery Services Market, 2018-2030: Rest of the World, Base Scenario (USD Billion)
Figure 13.7 Antibody Discovery Services: Market Attractiveness Analysis by Geography
Figure 13.8 Antibody Discovery Services Market, 2018-2030: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
Figure 13.9 Antibody Discovery Services Market, 2018, 2023, 2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Figure 13.10 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Figure 13.11 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Figure 13.12 Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated, Base Scenario (in Percentage)
Figure 13.13 Antibody Discovery Services Market, 2018-2030: Distribution by Type of Antibody Generated, Base Scenario (USD Billion)
Figure 13.13 Antibody Discovery Platforms Market, 2018-2030: Number of Licensing Deals  2018 and 2030
Figure 13.13 Antibody Discovery Platforms Market, 2018 2030: Upfront and Milestone Payments, 2018, 2025 and 2030
Figure 14.1 Humira®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.2 Rituxan®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.3 Herceptin®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.4 Remicade®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.5 Avastin®: Annual Sales, 2013-2017 (USD Billion)
Figure 14.1 Publication Analysis: Quarterly Distribution
Figure 14.2 Publication Analysis: Distribution by Key Journals
Figure 14.3 Publication Analysis: Distribution by Study Model
Figure 14.4 Publication Analysis: Distribution by Method Used for Humanization
Figure 14.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
Figure 14.7 Antibody Humanization Service and Platform Providers: Strengths Overview
Figure 14.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
Figure 14.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
Figure 14.10 Antibody Humanization Service and Platform Providers: Threats Overview
Figure 16.1 Future Opportunities Related to Upcoming Trends in Drug Discovery 
Figure 16.2 Number of Licensing Deals, 2011- 2017
Figure 17.1 Survey Insights: Distribution of Respondents by Location of Company Headquarters
Figure 17.2 Survey Insights: Distribution by Designation and Seniority Level
Figure 17.3 Survey Insights: Distribution by Antibody Discovery Stages
Figure 17.4 Survey Insights: Distribution by Antibody Discovery Methods
Figure 17.5 Survey Insights: Distribution by Type of Antibody Discovered
Figure 17.6 Survey Insights: Distribution by Location of Antibody Discovery Facility / Laboratory
Figure 17.7 Survey Insights: Distribution by Likely Market Size

List of Tables

Table 3.1 Antibody Isotypes: Key Features 
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 List of Antibody Discovery Service Providers
Table 5.2 Distribution by Antibody Discovery Steps
Table 5.3 Distribution by Antibody Discovery Methods 
Table 5.4 Distribution by Purpose of Antibody Discovery 
Table 5.5 Distribution by Type of Antibodies Discovered 
Table 5.6 Distribution by Animal Model Used 
Table 5.7 List of Antibody Discovery Platform Providers 
Table 5.8 Distribution by Antibody Discovery Methods 
Table 5.9 Distribution by Type of Antibodies Discovered 
Table 5.10 Distribution by Animal Model Used
Table 5.11 Antibody Discovery Platforms used for In-house Purposes
Table 6.1 Benchmark Analysis: Peer Groups
Table 7.1 Antibody Discovery Service Providers: Qualitative Comparison of Key Parameters
Table 8.1 Abwiz Bio: Future Outlook
Table 8.3 Aragen Bioscience: Future Outlook
Table 8.4 Integral Molecular: Future Outlook
Table 8.5 LakePharma: Future Outlook
Table 8.6 Abzena: Future Outlook
Table 8.7 MAB Discovery: Future Outlook
Table 8.8 PX'Therapeutics: Future Outlook
Table 8.9 ChemPartner: Future Outlook
Table 8.10 Viva Biotech: Future Outlook
Table 8.11 WuXi AppTec: Future Outlook
Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
Table 10.2 Distributed Bio: Future Outlook
Table 10.2 Invenra: Future Outlook
Table 10.3 OmniAb® Technology: Key Features
Table 10.4 OmniAb® Technology: Patent Information
Table 10.5 OmniChicken® Technology: Patent Information
Table 10.6 Ligand Pharmaceuticals: Future Outlook
Table 10.7 Sorrento Therapeutics: Future Outlook
Table 10.8 The Trianni Mouse™: Key Features
Table 10.9 TRIANNI: Future Outlook
Table 10.10 Single Cell Technology: Future Outlook
Table 10.11 AIMSelect Platform: Key Features
Table 10.12 AIMM Therapeutics: Future Outlook
Table 10.13 BioInvent: Future Outlook
Table 10.14 Kymab: Funding Instances
Table 10.15 Kymouse™: Key Features
Table 10.16 Kymab: Future Outlook
Table 10.17 H2L2 Platform: Key Features
Table 10.18 HCAb Platform: Key Features
Table 10.19 Harbour BioMed: Future Outlook
Table 11.1 Antibody Discovery Services and Platforms: Partnerships and Collaborations, 2011-2018
Table 12.1 Antibody Discovery Service and Platform Providers Market: Funding and Investments, 2009-2018
Table 12.2 Funding and Investment Analysis: Summary of Investments
Table 14.1 Top Ten Selling Therapeutic Antibodies, 2017
Table 14.1 Approved Monoclonal Antibodies: Information on Affinity
Table 14.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
Table 14.3 Antibody Humanization and Affinity Maturation: Description of Services and Platform Providers
Table 14.4 Antibody Humanization: Recent Publications
Table 14.5 Antibody Humanization: Modified CDR Grafting Methods
Table 16.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
Table 17.1 Survey Insights: Overview of Respondents
Table 17.2 Survey Insights: Designations and Seniority Levels
Table 17.3 Survey Insights: Antibody Discovery Stages
Table 17.4 Survey Insights: Antibody Discovery Methods
Table 17.5 Survey Insights: Type of Antibody Discovered
Table 17.6 Survey Insights: Location of Antibody Discovery Facility / Laboratory
Table 17.7 Survey Insights: Likely Current Market Size
Table 19.1 Approved Monoclonal Antibodies: Development Trend Analysis
Table 19.2 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Table 19.3 Antibody Discovery Service Providers: Distribution by Antibody Discovery Steps
Table 19.4 Antibody Discovery Service Providers: Distribution by Antibody Discovery Methods
Table 19.5 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 19.6 Antibody Discovery Service Providers: Distribution by Type of Antibodies Discovered 
Table 19.7 Antibody Discovery Service Providers: Distribution by Animal Model Used  
Table 19.8 Antibody Discovery Platform Providers: Distribution by Antibody Discovery Methods
Table 19.9 Antibody Discovery Platform Providers: Distribution by Type of Antibodies Discovered 
Table 19.10 Antibody Discovery Platform Providers: Distribution by Animal Model Used  
Table 19.11 Antibody Discovery Service and Platform Providers: Geographical Distribution
Table 19.12 Benchmark Analysis: Regional Distribution of Companies by Year of Establishment
Table 19.13 Abzena: Annual Revenues, 2013-H1 2018 (EUR Million)
Table 19.14 WuXi AppTec: Annual Revenues, 2012-Q1 2018 (USD Million)
Table 19.15 Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2018 (USD Million)
Table 19.16 Partnerships and Collaborations: Distribution by Number of Partnerships, 2011-2018
Table 19.17 Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2018
Table 19.18 Partnerships and Collaborations: Year-Wise Distribution by Type of Collaboration
Table 19.19 Partnerships and Collaborations: Distribution by Type of Partnership Among Platform and Service Providers
Table 19.20 Partnerships and Collaborations: Leading Players by Number of Partnerships
Table 19.21 Partnerships and Collaborations: Distribution by Key Focus Areas
Table 19.22 Partnerships and Collaborations: Novel Antibody Types (2017-2018)
Table 19.23 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year, 2009-2018 
Table 19.24 Funding and Investment Analysis: Distribution of Average Funding Amount by Year, 2009-2018 (USD Million)
Table 19.25 Funding and Investment Analysis:  Distribution of Amount Invested by Year, 2009-2018 (USD Million)
Table 19.26 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Table 19.27 Funding and Investment Analysis: Number of Funding Instances by Type of Funding, 2009-2013 and 2014-2018  
Table 19.28 Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
Table 19.29 Funding and Investment Analysis: Distribution by Amount of Funding, 2009-2018
Table 19.30 Funding and Investment Analysis: Most Active Players 
Table 19.31 Funding and Investment Analysis: Most Active Investors 
Table 19.32 Antibody Discovery Services Market, 2018-2030: Conservative Scenario (USD Billion)
Table 19.33 Antibody Discovery Services Market, 2018-2030: Base Scenario (USD Billion)
Table 19.34 Antibody Discovery Services Market, 2018-2030: Optimistic Scenario (USD Billion)
Table 19.35 Antibody Discovery Services Market, 2018 and 2030:  Distribution by Region (USD Billion)
Table 19.36 Antibody Discovery Services Market, 2018-2030: North America, Conservative Scenario (USD Billion)
Table 19.37 Antibody Discovery Services Market, 2018-2030: North America, Base Scenario (USD Billion)
Table 19.38 Antibody Discovery Services Market, 2018-2030: North America, Optimistic Scenario (USD Billion)
Table 19.39 Antibody Discovery Services Market, 2018-2030: Europe, Conservative Scenario (USD Billion)
Table 19.40 Antibody Discovery Services Market, 2018-2030: Europe, Base Scenario (USD Billion)
Table 19.41 Antibody Discovery Services Market, 2018-2030: Europe, Optimistic Scenario (USD Billion)
Table 19.42 Antibody Discovery Services Market, 2018-2030: China, Conservative Scenario (USD Billion)
Table 19.43 Antibody Discovery Services Market, 2018-2030: China, Base Scenario (USD Billion)
Table 19.44 Antibody Discovery Services Market, 2018-2030: China, Optimistic Scenario (USD Billion)
Table 19.45 Antibody Discovery Services Market, 2018-2030: Rest of the World, Conservative Scenario (USD Billion)
Table 19.46 Antibody Discovery Services Market, 2018-2030: Rest of the World, Base Scenario (USD Billion)
Table 19.47 Antibody Discovery Services Market, 2018-2030: Rest of the World, Optimistic Scenario (USD Billion)
Table 19.48 Antibody Discovery Services: Market Attractiveness Analysis by Region
Table 19.49 Antibody Discovery Services Market, 2018-2030: Distribution by Steps Involved in Antibody Discovery Process, Conservative Scenario (USD Billion)
Table 19.50 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps, Base Scenario (USD Billion)
Table 19.51 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps, Optimistic Scenario (USD Billion)
Table 19.52 Antibody Discovery Services Market, 2018, 2023, 2030: Distribution by Antibody Discovery Methods (USD Billion)
Table 19.53 Antibody Discovery Services Market, 2018-2028: Distribution by Antibody Discovery Methods, Conservative Scenario (USD Billion)
Table 19.54 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
Table 19.55 Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Optimistic Scenario (USD Billion)
Table 19.56 Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
Table 19.57 Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated (USD Billion)
Table 19.58 Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated, Conservative Scenario (USD Billion)
Table 19.59 Antibody Discovery Services Market, 2018 and 2030: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
Table 19.60 Antibody Discovery Services Market, 2018 and 2030: Distribution by Nature of Antibody Generated, Optimistic Scenario (USD Billion)
Table 19.61 Antibody Discovery Platforms Market, 2018 and 2030: Number of Licensing Deals 2018 and 2030 (USD Billion)
Table 19.62 Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030
Table 19.63 Antibody Discovery Platform Providers: Number of Licensing Deals, 2011- 2017
Table 19.64 Survey Insights: Distribution of Respondents by Location of Company Headquarters
Table 19.65 Survey Insights: Distribution by Designation and Seniority Level
Table 19.66 Survey Insights: Distribution by Antibody Discovery Stages
Table 19.67 Survey Insights: Distribution by Antibody Discovery Methods
Table 19.68 Survey Insights: Distribution by Type Antibody Discovered
Table 19.69 Survey Insights: Location of Antibody Discovery Facility / Laboratory
Table 19.70 Survey Insights: Likely Current Market Size

List of Companies

The following companies and organizations have been mentioned in the report:

  1.  4-Antibody
  2.  A*STAR's Genome Institute of Singapore
  3.  AB Biosciences
  4.  Ab Studio
  5.  ABBA Therapeutics
  6.  AbBioSci
  7.  AbbVie
  8.  AbCellera
  9.  AbCheck
  10.  Abeome 
  11.  AbGenics Life Sciences
  12.  Abgent
  13.  Ablexis
  14.  Abpro
  15.  Absolute Antibody
  16.  Abwiz Bio
  17.  Abzena
  18.  Abzyme Therapeutics
  19.  Accel
  20.  Acceleron Pharma
  21.  Accurus Biosciences
  22.  Achaogen
  23.  ACROBiosystems
  24.  ACYTE Biotech
  25.  Adagene
  26.  Adimab 
  27.  Aduro Biotech
  28.  Advantech Capital
  29.  Agenus
  30.  AIMM Therapeutics
  31.  Aitua
  32.  Akeagen
  33.  Alder BioPharmaceuticals
  34.  Alector
  35.  Alere
  36.  Alexandria Real Estate Equities
  37.  Alexion Pharmaceuticals
  38.  Ally Bridge Group 
  39.  Amdec Group
  40.  Amgen
  41.  Ampersand Capital Partners
  42.  AnaptysBio
  43.  AP Biosciences
  44.  Apexigen
  45.  Aquila Capital
  46.  Aragen Bioscience
  47.  ARCH Venture Partners
  48.  Argenx
  49.  Aridis Pharmaceuticals
  50.  Aristi Biotech
  51.  Astellas Venture Management 
  52.  AstraZeneca
  53.  Atlas Venture
  54.  Atreca
  55.  AvantGen
  56.  Avlar BioVentures
  57.  AxioMx
  58.  Ballast Point Ventures
  59.  Bayer
  60.  BASF 
  61.  BBI Group
  62.  BeiGene
  63.  Beijing Shijilongxin Investment 
  64.  Berkeley Lights
  65.  Bill & Melinda Gates Foundation
  66.  BioAtla
  67.  Biogen
  68.  BioGeneration Ventures
  69.  BioInvent International
  70.  BioLauncher 
  71.  Biomirex
  72.  BioNTech
  73.  Bio-Rad
  74.  BioRap Technologies
  75.  Biosin  
  76.  BIOTEM
  77.  Birchmere Labs
  78.  Bird Rock Bio
  79.  Blue Sky BioServices
  80.  bluebird bio
  81.  Boehringer Ingelheim
  82.  Borealis Ventures
  83.  Bristol-Myers Squibb
  84.  Brigham and Women's Hospital 
  85.  Burrage Capital
  86.  BVF Partners
  87.  Canaan Partners
  88.  Cambridge Antibody Technology
  89.  Capra Science Antibodies
  90.  Case Western Reserve University School of Medicine
  91.  Catalent Biologics 
  92.  Celexion 
  93.  Celgene
  94.  Cellectis
  95.  Celltrion
  96.  Centers for Disease Control and Prevention
  97.  ChemBio Discovery Solutions
  98.  ChemPartner
  99.  Chiome Bioscience
  100.  Chugai Pharmaceutical
  101.  Chugai Pharmabody Research
  102.  Cisbio
  103.  CNA Development
  104.  Compass Therapeutics
  105.  Compugen
  106.  Commission for Technology and Innovation
  107.  ContraFect 
  108.  Corixa
  109.  Cormorant Pharmaceuticals
  110.  Cosmo Pharmaceuticals 
  111.  Creative Biolabs
  112.  Crescendo Biologics
  113.  Cresset Biomolecular Discovery
  114.  Crucell
  115.  Crystal Bioscience
  116.  Cullinan Oncology
  117.  Cytogen
  118.  DAFNA Capital Management
  119.  Daiichi Sankyo
  120.  Dako
  121.  Dana-Farber Cancer Institute
  122.  DaTaMabs
  123.  Defense Threat Reduction Agency
  124.  Department of Health and Human Services 
  125.  Digital Proteomics
  126.  Distributed Bio
  127.  DJS Antibodies
  128.  Dyax
  129.  Effimune
  130.  Elan
  131.  Eli Lilly
  132.  Elusys Therapeutics
  133.  EMBL Ventures
  134.  Emergent BioSolutions
  135.  Emory University
  136.  Enthera
  137.  Enumeral
  138.  EpiCypher
  139.  EpimAb Biotherapeutics
  140.  Erasmus MC Biomedical Fund
  141.  Essex Bio-Technology
  142.  Eureka Therapeutics
  143.  European Investment Bank
  144.  EVA Basel
  145.  Evotec
  146.  Exiris
  147.  FairJourney Biologics
  148.  Ferring Pharmaceuticals
  149.  Five Prime Therapeutics
  150.  Flanders Innovation and Entrepreneurship
  151.  Floodgate Fund 
  152.  Forbion Capital Partners
  153.  Fred Hutchinson Cancer Research Center
  154.  Fresenius
  155.  F-star
  156.  Fusion Antibodies
  157.  G&P Biosciences
  158.  Genedata 
  159.  GeneBeyond
  160.  GeneFrontier
  161.  Genentech
  162.  Genetix
  163.  Genmab
  164.  Genor Biopharma
  165.  GenScript
  166.  Genzyme
  167.  Georgia Institute of Technology
  168.  GigaGen
  169.  Gilead Sciences
  170.  GlaxoSmithKline
  171.  Glenmark Pharmaceuticals
  172.  GlycoNex
  173.  Grenoble Hospital 
  174.  GTJA Investment Group
  175.  GVK Biosciences
  176.  Harbour BioMed
  177.  Harpoon Therapeutics
  178.  HD Biosciences
  179.  HealthCare Ventures
  180.  Henlix Biotech
  181.  Heptares Therapeutics
  182.  Hercules Capital
  183.  HitGen
  184.  HQL Pharmaceuticals
  185.  Humabs BioMed
  186.  Human Genome Sciences
  187.  IBC Generium
  188.  Ibex Biosciences
  189.  IGEM Therapeutics
  190.  Igenica Biotherapeutics
  191.  ImClone Systems 
  192.  Immune Biosolutions
  193.  Immunex 
  194.  ImmunoChina Pharmaceuticals
  195.  Immunologix
  196.  Immunome
  197.  Immunomedics
  198.  Immunomic Therapeutics
  199.  ImmunoPrecise Antibodies
  200.  Imperial Innovations
  201.  In-Cell-Art
  202.  Innovate UK
  203.  Innovative Targeting Solutions
  204.  Innovent Biologics
  205.  Institut Pasteur
  206.  Institute for the Promotion of Innovation by Science and Technology
  207.  Integral Molecular
  208.  Intrexon 
  209.  Invenra
  210.  IONTAS
  211.  Isogenica
  212.  iTeos Therapeutics
  213.  Janssen Biotech
  214.  Jazz Pharmaceuticals
  215.  Jiangsu Hengrui Medicine
  216.  Johnson & Johnson
  217.  Jounce Therapeutics
  218.  Juno Therapeutics 
  219.  Kaken Pharmaceutical
  220.  KBC Private Equity
  221.  KindredBio
  222.  King Star   
  223.  Kite Pharma
  224.  Kodiak Sciences
  225.  Kymab
  226.  Kyowa Hakko Kirin
  227.  LakePharma
  228.  Leland Stanford Junior University
  229.  LEO Pharma
  230.  Les Laboratoires Servier
  231.  Life Sciences Partners
  232.  Ligand Pharmaceuticals
  233.  Lilly Asia Ventures
  234.  LYFE Capital
  235.  MAB Discovery
  236.  MabPlex
  237.  MabSpace Biosciences
  238.  MabVax Therapeutics
  239.  MacroGenics
  240.  Magenta Therapeutics
  241.  Malin 
  242.  Massachusetts General Hospital
  243.  MassBiologics
  244.  Maverick Therapeutics
  245.  MD Anderson Cancer Center
  246.  Medarex 
  247.  Medical Research Council
  248.  MediMabs
  249.  MedImmune
  250.  Meditope Biosciences
  251.  MEMO Therapeutics
  252.  Memorial Sloan Kettering Cancer Center
  253.  Merck
  254.  Mersana Therapeutics
  255.  Merus
  256.  MidCap Financial
  257.  Millennium Pharmaceuticals
  258.  Mitsubishi Tanabe Pharma
  259.  ModiQuest Research
  260.  Molcure
  261.  Molecular Devices
  262.  Molecular Templates
  263.  Moradec
  264.  MorphoSys
  265.  MPM Capital
  266.  MSM Protein Technologies
  267.  National Institute of Allergy and Infectious Diseases
  268.  National Institutes of Health
  269.  NB Health Laboratory
  270.  NBE Therapeutics
  271.  NeoClone
  272.  Nst
  273.  Neurimmune
  274.  NGM Biopharmaceuticals
  275.  North Coast Biologics
  276.  NovaRock Biotherapeutics
  277.  Novartis
  278.  Novimmune
  279.  Novo Nordisk
  280.  Numab
  281.  NXT Ventures
  282.  Oak BioSciences
  283.  Olympic Protein Technologies 
  284.  Omnes Capital
  285.  OncoMed Pharmaceuticals
  286.  Oncobiologics
  287.  Oncothyreon
  288.  Ono Pharmaceutical
  289.  Open Monoclonal Technology
  290.  OrbiMed Advisors
  291.  Organon Teknika
  292.  ORI Healthcare Fund
  293.  OriMAbs
  294.  Ossianix
  295.  Oxford BioTherapeutics
  296.  Ozyme
  297.  Palatin Technologies
  298.  Pfizer
  299.  PharmAthene
  300.  Phylogica 
  301.  Pierre Fabre 
  302.  Polaris Partners 
  303.  Porton Pharma Solutions
  304.  Potenza Therapeutics
  305.  Prime Value Capital Management
  306.  ProteoGenix
  307.  Proxima Ventures
  308.  Pure Biologics
  309.  PX'Therapeutics
  310.  Qianhai Fund of Funds
  311.  Qiming Venture Partners
  312.  QoolAbs
  313.  Quanta BioDesign
  314.  Queen Mary University of London
  315.  RayBiotech
  316.  Redalpine Venture Partners
  317.  Regeneron Pharmaceuticals
  318.  Research Corporation Technologies
  319.  ResearchPoint Global
  320.  ribOvax Biotechnologies
  321.  Roche
  322.  Rx Biosciences
  323.  SAB Biotherapeutics
  324.  Sanofi
  325.  Scripps Research Institute 
  326.  Sea Lane Biotechnologies
  327.  Seattle Genetics
  328.  Selexis
  329.  Sequoia Capital 
  330.  Sevion Therapeutics
  331.  Shanghai Jianxin Capital
  332.  ShangPharma Innovation
  333.  Shenogen Pharma
  334.  Shenzhen Capital Group
  335.  Shenzhen Hepalink Pharmaceutical
  336.  Shenzhen Innovation Investment Group  
  337.  Shenzhen Xinnuo Health Industry Investment
  338.  Shire
  339.  Siamab Therapeutics
  340.  Silicon Valley Bank
  341.  Silverton Partners
  342.  Singapore Immunology Network
  343.  Single Cell Technology
  344.  Sino Biological
  345.  Soligenix
  346.  Sorrento Therapeutics
  347.  SOTIO
  348.  Specifica
  349.  Spectrum Pharmaceuticals
  350.  Sphere Fluidics
  351.  Stanford University
  352.  Sucampo Pharmaceuticals
  353.  Surface Oncology
  354.  Sutro Biopharma
  355.  SV Life Sciences
  356.  Swedish Orphan Biovitrum
  357.  Symphogen
  358.  Synthetic Biologics
  359.  Synthon Biopharmaceuticals
  360.  Takeda Pharmaceutical
  361.  Tanabe Research Laboratories
  362.  TeneoBio
  363.  TetraGenetics
  364.  Teva Pharmaceutical
  365.  The French National Institute of Health and Medical Research
  366.  Theraclone Sciences
  367.  Theranyx
  368.  Tizona Therapeutics
  369.  Torch Biosciences
  370.  Transgene
  371.  TransGenic
  372.  Trellis Bioscience
  373.  TRIANNI
  374.  Tri-Institutional Therapeutics Discovery Institute
  375.  TriWise Capital
  376.  Twist Bioscience
  377.  U3 Pharma
  378.  UCB
  379.  United Therapeutics
  380.  University of California
  381.  University of Southampton
  382.  University of Texas 
  383.  University of Turku
  384.  Vaccinex
  385.  Valeant Pharmaceuticals
  386.  venBio
  387.  Versant Ventures
  388.  VI Ventures
  389.  Viva Biotech
  390.  Viventia Bio
  391.  Wellcome Trust Sanger Institute
  392.  Woodford Investment Management
  393.  WuXi AppTec
  394.  Wyeth
  395.  XBiotech
  396.  xCella Biosciences
  397.  XOMA
  398.  YUMAB
  399.  YuRoGen Biosystems
  400.  Zebra Biologics
  401.  ZENOAQ
  402.  Zurich Cantonal Bank 
  403.  Zymeworks
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com